Select your country and language
Singapore
Malaysia
Indonesia
Brunei

A/Prof. Lim Soo Teik

A/Prof. Lim Soo Teik

Designation: Deputy Medical Director and Senior Consultant
Director of Cardiac Catheterisation Laboratory

Specialization:
Cardiology

Language spoken: English, Mandarin, Bahasa Melayu

Hospital Affiliation:
National Heart Centre Singapore (NHCS)


Clinic Address:
National Heart Centre Singapore
5 Hospital Drive
Singapore 169609

Operating Hours: Mon to Fri: 8.30am - 5.30pm
Sat, Sun and PH: Closed


Adjunct Associate Professor Lim Soo Teik is Deputy Medical Director, National Heart Centre Singapore (NHCS), and Director of the Cardiac Catheterisation Laboratory and Senior Consultant with the Department of Cardiology at NHCS.

He is also the Deputy Academic Vice Chair, Training & Education in the Cardiovascular Sciences Academic Clinical Programme.

Adj Assoc Prof Lim's subspecialty interest is in interventional cardiology. He sub-specialises in coronary angioplasty and stenting, as well as peripheral vascular interventional treatment for diseases in carotid, renal, iliac and lower limb vessels. Additionally, he has a special interest in the management of pulmonary hypertension, dyslipidaemia and hypertension.

Adj Assoc Prof Lim graduated with his Bachelor of Medicine and Surgery in 1989 and his Master of Medicine (Internal Medicine) in 1993 from the National University of Singapore. Adj Assoc Prof Lim has been a Member of Royal College of Physician, Edinburgh, UK since 1993; Fellow of the Academy of Medicine Singapore since 2000 and Fellow of the Royal College of Physicians, Edinburgh, UK since 2004. He completed his fellowship in Interventional Cardiology at the William Beaumont Hospital, Royal Oak, Michigan, USA in 1999 and Peripheral Vascular Intervention at the St. Elizabeth Hospital, Boston, Massachusetts, USA in 2000.

Adj Assoc Prof Lim is also a caring clinician who has won numerous internal and external service awards. He is a meticulous doctor, and would always listen to patients' concerns, providing proper reassurance and guidance.

Professional Positions and Memberships:
Chairman of the Chapter of Cardiology, Academy of Medicine, Singapore. (2009-2013)
Honorary General Secretary of the Singapore Cardiac Society (2011/2012; 2012/2013)
Council Member of the Singapore Cardiac Society (2003/2004; 2004/2005; 2005/2006; 2009/2010; 2010/2011; 2013/2014)
Secretary General of the Asia-Pacific Society of Interventional Cardiology (APSIC) (2013-2016)
Member of the JCST Exit Examination Committee for Cardiology, Academy of Medicine (2016–2017)
Expert Panel Member of the International Atomic Energy Agency (IAEA) Radiation Protection in Interventional Cardiology (2006 -- 2012)
Chairman of the Organising Committee, Singapore Cardiac Society 16th Annual Scientific Meeting (2004)
Chairperson of the Organising Committee, World Heart Day 2009, Singapore Heart Foundation (2009).
Deputy Chairperson of the Organising Committee, World Heart Day 2008, Singapore Heart Foundation (2008).
Honorary Auditor of the Singapore Cardiac Society (2002/2003; 2008/2009)

Education:
MBBS
MMed (Int Med)
MRCPE (Int Med)
FRCP (Edin)
FAMS
FESC
FAsCC
FSCAI

Board Certifications:
Registered as a Specialist in Cardiology by the Singapore Medical Council

Awards and Publications
Haude M, Ince H, Abizaid A, Lemos PA, Birgelen C, Toelg R, Pedro AL, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Lim ST, Escaned J, Onuma Y, Garcia-Garcia H, Waksman R. "Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.” Eur Heart J 2016 (doi:10.1093/eurheartj/ehw196). Published 2016 May 17.

Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Lim ST, Escaned J, Garcia HM, Waksman R. Safety and performance of the second-generation drug-eluting absorbable metal scaff old in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 2015 Oct 12 ( http://dx.doi.org/10.1016/S0140-6736(15)00447-X)

Back to top
Need help?
For product enquiries
For customer service
Get Help
Contact Us
Make a claim
Buy General Insurance
Great Eastern Holdings Ltd | Great Eastern Life Assurance Co Ltd | Great Eastern General Insurance Ltd
Great Eastern Holdings Ltd | Great Eastern Life Assurance Co Ltd | Great Eastern General Insurance Ltd